New Drug IC7Fc Shows Promise in Combating Both Heart Disease and Type 2 Diabetes
Melbourne/Leiden (pte002/06.11.2025/06:05) โค- โA novel experimental drug,IC7Fc,developedโ jointly by researchers at Monash University and Leiden University Hospital,demonstratesโฃ a dual benefit: reducing the risk of heart disease and fighting type 2 diabetes. Testing on mice with cardiovascular diseases revealed the โขdrug lowers cholesterol levels and prevents inflammation.
IC7Fc, โan artificial protein, mimics the body’s interleukin-6 signaling but without triggering harmful inflammation. Rather, itโ regulates metabolism and promotes tissue repair. Researchers found that mice treated solelyโฃ with IC7Fc โคexhibited โthe lowest levels of arterial plaque buildup and maintained safe insulin levels, alongside minimal inflammation, when fed a cholesterol-rich diet for seven weeks.The study compared IC7Fc’s effects against aโค statin, both IC7Fc and โa โคstatin, and a placebo.
The development comes as forecasts predict over 1.3 billion people worldwide will be affectedโค by type โ2 diabetes by 2050, a disease frequently occurring alongside โคcardiovascular disease โค- the leading cause of death globally.
“Previous studies had already shown that IC7Fc can help in the treatment of type 2 โdiabetes, โขa metabolic disease,” stated Mark Febbraio from the University of Melbourne. “Our new study shows that it can also reduce atherosclerosis. Itโค slows the deposition of fats in the โarteries, which threaten the supplyโค of oxygen to the heart by inhibiting blood flow.”
IC7Fc is currently experimental and not yet approved for use.